rs1057519825
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Additionally, ARQ 531 inhibits CLL cell survival and suppresses BCR-mediated activation of C481S BTK and PLCγ2 mutants, which facilitate clinical resistance to ibrutinib.<b>Significance:</b> This study characterizes a rationally designed kinase inhibitor with efficacy in models recapitulating the most common mechanisms of acquired resistance to ibrutinib.
|
30093506 |
2018 |
rs1057519825
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Collectively, these data provide a basis for further preclinical study of BTK PROTACs as a novel strategy for treatment of C481S mutant CLL.
|
29851337 |
2018 |
rs1057519825
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLL.
|
30018078 |
2018 |
rs1057519826
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Additionally, ARQ 531 inhibits CLL cell survival and suppresses BCR-mediated activation of C481S BTK and PLCγ2 mutants, which facilitate clinical resistance to ibrutinib.<b>Significance:</b> This study characterizes a rationally designed kinase inhibitor with efficacy in models recapitulating the most common mechanisms of acquired resistance to ibrutinib.
|
30093506 |
2018 |
rs1057519826
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Collectively, these data provide a basis for further preclinical study of BTK PROTACs as a novel strategy for treatment of C481S mutant CLL.
|
29851337 |
2018 |
rs1057519826
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLL.
|
30018078 |
2018 |
rs1057519825
|
|
|
0.050 |
GeneticVariation |
BEFREE |
We have also made the novel and clinically relevant discovery that inhibition of HDAC induces the BTK-targeting miRs in ibrutinib-sensitive and resistant CLL to effectively reduce both wild-type and C481S-mutant BTK.
|
27756747 |
2016 |
rs1057519826
|
|
|
0.050 |
GeneticVariation |
BEFREE |
We have also made the novel and clinically relevant discovery that inhibition of HDAC induces the BTK-targeting miRs in ibrutinib-sensitive and resistant CLL to effectively reduce both wild-type and C481S-mutant BTK.
|
27756747 |
2016 |
rs1057519825
|
|
|
0.050 |
GeneticVariation |
BEFREE |
We previously reported the identification of BTK(C481S) mutation in a CLL patient who progressed following 21-month ibrutinib therapy.
|
25189416 |
2015 |
rs1057519826
|
|
|
0.050 |
GeneticVariation |
BEFREE |
We previously reported the identification of BTK(C481S) mutation in a CLL patient who progressed following 21-month ibrutinib therapy.
|
25189416 |
2015 |